Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
The power of Python trumps Excel workbooks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results